よむ、つかう、まなぶ。
参考資料14 高齢者がん医療Ｑ＆Ａ総論（厚生労働科学研究「高齢者がん診療指針策定に必要な基盤整備に関する研究」） (215 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_28073.html |
| 出典情報 | がん対策推進協議会（第82回 9／20）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
文献
1)
Sawhney et al. Physiologic aspects of aging: impact on cancer management and decision
making, part I. Cancer J. 2005;11:449-460
2)
Superfin D et al. Commentary: Oncologic drugs in patients with organ dysfunction: a
summary. Oncologist. 2007;12:1070-1083
3)
Venook AP et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic
dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998;16:1811-1819
4)
岸愼治, 上田孝典. 抗癌薬の至適投与. 腎と透析. 2013;74:377-382
5)
Gomez H et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with
CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification
of two age subgroups with differing hematologic toxicity. J Clin Oncol. 1998;16:2352-2358
6)
Schild SE et al. The outcome of combined-modality therapy for stage III non-small-cell lung
cancer in the elderly. J Clin Oncol. 2003;21:3201-3206
7)
Smith TJ et al. 2006 update of recommendations for the use of white blood cell growth
factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187-3205
8)
Ania BJ et al. Incidence of anemia in older people: an epidemiologic study in a well defined
population. J Am Geriatr Soc. 1997;45:825-831
9)
Bennett CL et al. Venous thromboembolism and mortality associated with recombinant
erythropoietin and darbepoetin administration for the treatment of cancer-associated
anemia. JAMA. 2008;299:914-924
10) Hershman DL et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly
patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:3159-3165
11) Argyriou AA et al. Is advanced age associated with increased incidence and severity of
chemotherapy-induced peripheral neuropathy? Support Care Cancer. 2006;14:223-229
12) Gottlieb D et al. The neurotoxicity of high-dose cytosine arabinoside is age-related. Cancer.
1987;60:1439-1441
13) Bozzetti F. Forcing the vicious circle: sarcopenia increases toxicity, decreases response to
chemotherapy and worsens with chemotherapy. Ann Oncol. 2017;28:2107-2118
207
1)
Sawhney et al. Physiologic aspects of aging: impact on cancer management and decision
making, part I. Cancer J. 2005;11:449-460
2)
Superfin D et al. Commentary: Oncologic drugs in patients with organ dysfunction: a
summary. Oncologist. 2007;12:1070-1083
3)
Venook AP et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic
dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998;16:1811-1819
4)
岸愼治, 上田孝典. 抗癌薬の至適投与. 腎と透析. 2013;74:377-382
5)
Gomez H et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with
CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification
of two age subgroups with differing hematologic toxicity. J Clin Oncol. 1998;16:2352-2358
6)
Schild SE et al. The outcome of combined-modality therapy for stage III non-small-cell lung
cancer in the elderly. J Clin Oncol. 2003;21:3201-3206
7)
Smith TJ et al. 2006 update of recommendations for the use of white blood cell growth
factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187-3205
8)
Ania BJ et al. Incidence of anemia in older people: an epidemiologic study in a well defined
population. J Am Geriatr Soc. 1997;45:825-831
9)
Bennett CL et al. Venous thromboembolism and mortality associated with recombinant
erythropoietin and darbepoetin administration for the treatment of cancer-associated
anemia. JAMA. 2008;299:914-924
10) Hershman DL et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly
patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:3159-3165
11) Argyriou AA et al. Is advanced age associated with increased incidence and severity of
chemotherapy-induced peripheral neuropathy? Support Care Cancer. 2006;14:223-229
12) Gottlieb D et al. The neurotoxicity of high-dose cytosine arabinoside is age-related. Cancer.
1987;60:1439-1441
13) Bozzetti F. Forcing the vicious circle: sarcopenia increases toxicity, decreases response to
chemotherapy and worsens with chemotherapy. Ann Oncol. 2017;28:2107-2118
207